精准免疫肿瘤学市场规模、份额、成长分析、按癌症类型、按治疗类型、按生物标记、按最终用途、按地区 - 行业预测，2025-2032 年

2023年全球精准免疫肿瘤市场规模为606.5亿美元，从2024年的672亿美元成长到2032年的1,526.5亿美元，预测期（2025-2032）预计复合年增长率为10.8%。

精准免疫肿瘤学正迅速成为癌症治疗的开创性方法，重点在于考虑患者遗传特征、肿瘤特征和免疫反应的个人化治疗。与传统治疗方法相比，这种个人化策略不仅提高了治疗效果，而且还最大限度地减少了副作用，为长期缓解带来了希望。先进的诊断在识别癌细胞上的特异性基因突变和蛋白质以及实现有针对性的干预方面发挥关键作用。临床试验已经显示出有希望的结果，特别是在患有抗治疗性癌症的患者中，并且已经显示出显着的患者反应。随着製药公司意识到精准免疫肿瘤学的变革潜力，在这一领域进行了大量投资，这标誌着癌症治疗发展的一个重要里程碑，并凸显了市场的光明前景。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 宏观经济指标
• 价值链分析
• 价格分析
• 技术分析
• 专利分析
• 研发线产品分析
• 案例研究分析

精准免疫肿瘤学市场规模：依癌症类型分类

• 市场概况
• 肺癌
• 乳癌
• 摄护腺癌
• 恶性黑色素瘤
• 其他的

按治疗类型分類的精准免疫肿瘤学市场规模

• 市场概况
• 查核点抑制剂
• CAR-T细胞疗法
• 癌症疫苗
• 其他的

精准免疫肿瘤学市场规模：依生物标记分类

• 市场概况
• PD-L1
• BRCA
• KRAS
• EGFR
• 其他的

按最终用途分類的精准免疫肿瘤学市场规模

• 市场概况
• 医院
• 诊所
• 调查机构
• 其他的

精准免疫肿瘤学市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Adaptimmune Therapeutics plc（UK）
• Agenus Inc.（US）
• Amgen Inc.（US）
• AstraZeneca plc（UK）
• Bristol Myers Squibb Company（US）
• Celgene Corporation（US）
• Eli Lilly and Company（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Gilead Sciences, Inc.（US）
• GlaxoSmithKline plc（UK）
• Iovance Biotherapeutics, Inc.（US）
• Juno Therapeutics, Inc.（US）
• Kite Pharma, Inc.（US）
• Merck & Co., Inc.（US）
• Neon Therapeutics, Inc.（US）
• Novartis AG（Switzerland）
• Pfizer Inc.（US）
• Sanofi SA（France）
• Seattle Genetics, Inc.（US）
• Takeda Pharmaceutical Company Limited（Japan）

结论和建议

Global Precision Immuno-Oncology Market size was valued at USD 60.65 billion in 2023 and is poised to grow from USD 67.20 billion in 2024 to USD 152.65 billion by 2032, growing at a CAGR of 10.8% during the forecast period (2025-2032).

Precision immuno-oncology is swiftly gaining traction as a pioneering approach in cancer treatment, focusing on tailored therapies that consider patients' genetic profiles, tumor characteristics, and immune responses. This personalized strategy not only enhances treatment efficacy but also minimizes side effects compared to conventional therapies, offering hope for long-term remissions. Advanced diagnostics play a crucial role in identifying unique genetic mutations and proteins on cancer cells, enabling targeted interventions. Clinical trials have demonstrated encouraging results, particularly in patients with treatment-resistant cancers, showcasing remarkable patient responses. The sector is witnessing substantial investment as pharmaceutical companies recognize the transformative potential of precision immuno-oncology, marking a significant milestone in the evolution of cancer care and highlighting its promising future in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segmental Analysis

Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the rising incidence of cancer worldwide. As cancer remains a pressing health issue, the need for advanced treatment options is becoming increasingly urgent. Traditional therapies like chemotherapy and radiation often have severe limitations and side effects, leading to a push for more innovative solutions. Precision immuno-oncology stands out by harnessing the body's immune system to combat cancer effectively. This tailored approach enables the development of targeted therapies based on individual genetic profiles, tumor characteristics, and immune responses, potentially enhancing treatment efficacy while minimizing adverse effects, thus propelling market demand.

Restraints in the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market faces significant challenges primarily due to the high costs associated with these advanced therapies. Unlike traditional cancer treatments, precision immuno-oncology offers a personalized approach, which inherently involves complex and expensive methodologies. This heightened expense can restrict patient access, particularly for those in developing nations where healthcare resources are scarce. Factors such as exorbitant research and development expenditures, the requirement for specialized equipment, and the processes involved in biomarker testing further escalate costs. The unique treatment plans tailored for individual patients add another layer of expense, creating disparities in access to effective cancer care, especially for individuals from low- and middle-income regions, thereby exacerbating existing inequities in cancer treatment and outcomes.

Market Trends of the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology market is witnessing significant growth driven by the increasing adoption of combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This trend is rooted in the rising awareness of the enhanced treatment efficacy and the potential to combat drug resistance inherent in singular therapies. As research continues to yield promising results-especially in complex cancers such as lung cancer and melanoma-clinicians are increasingly leveraging these multi-faceted treatment approaches to improve patient outcomes. Furthermore, advancements in biomarker identification and personalized medicine are expected to further propel market expansion, catering to a more tailored cancer treatment landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Pipeline Product Analysis
• Case Study Analysis

Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Melanoma
• Others

Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Checkpoint Inhibitors
• Car T Cell Therapy
• Cancer Vaccines
• Others

Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2025-2032)

• Market Overview
• PD-L1
• BRCA
• KRAS
• EGFR
• Others

Global Precision Immuno-Oncology Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital
• Clinics
• Research Institutes
• Others

Global Precision Immuno-Oncology Market Size & CAGR (2025-2032)

• North America (Cancer Type, Treatment Type, Biomarker, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment Type, Biomarker, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neon Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations